Literature DB >> 14605631

Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer.

Ricardo Santos1, Athanasios Colonias, David Parda, Mark Trombetta, Richard H Maley, Robin Macherey, Susan Bartley, Tibetha Santucci, Robert J Keenan, Rodney J Landreneau.   

Abstract

BACKGROUND: Sublobar resection (SR) can be performed in high-risk non-small-cell lung carcinoma (NSCLC) patients but is associated with an increased local recurrence. This abstract reviews our intraoperative (125)Iodine brachytherapy experience after SR in high-risk Stage I NSCLC patients and compares these results with our previous series of SR alone in similar patients.
METHODS: One hundred two Stage I NSCLC patients who underwent SR alone were compared with 101 Stage I patients who underwent SR and intraoperative (125)Iodine brachytherapy placed over the SR staple line.
CONCLUSION: Local recurrence after SR and (125)Iodine brachytherapy (2%) in high-risk Stage I NSCLC patients was significantly less than after SR alone (18.6%). This safe, pulmonary function-preserving and practical intraoperative brachytherapy method should be considered when SR is used as a "compromise" therapy in these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605631     DOI: 10.1016/s0039-6060(03)00327-1

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  22 in total

1.  Adjuvant treatment for elderly patients with early-stage lung cancer treated with limited resection.

Authors:  Rajwanth R Veluswamy; Grace Mhango; Marcelo Bonomi; Alfred I Neugut; Dawn L Hershman; Melissa D Aldridge; Juan P Wisnivesky
Journal:  Ann Am Thorac Soc       Date:  2013-12

Review 2.  Radical sublobar resection for lung cancer.

Authors:  Morihito Okada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-04-10

3.  Dosimetric characterization of the GammaClip™ 169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection.

Authors:  Blake Currier; John J Munro; David C Medich
Journal:  Med Phys       Date:  2013-08       Impact factor: 4.071

4.  Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.

Authors:  Jun-ichi Nitadori; Adam J Bograd; Kyuichi Kadota; Camelia S Sima; Nabil P Rizk; Eduardo A Morales; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  J Natl Cancer Inst       Date:  2013-08-07       Impact factor: 13.506

Review 5.  Modern impact of video assisted thoracic surgery.

Authors:  Rachit D Shah; Thomas A D'Amico
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 6.  The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?

Authors:  Gregory M M Videtic; Kevin L Stephans
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

Review 7.  Emerging treatment options in the management of non-small cell lung cancer.

Authors:  Pier Luigi Filosso; Alberto Sandri; Alberto Oliaro; Andrea Riccardo Filippi; Maria Carla Cassinis; Umberto Ricardi; Paolo Olivo Lausi; Sofia Asioli; Enrico Ruffini
Journal:  Lung Cancer (Auckl)       Date:  2011-06-08

8.  125I inhibited the NSCLC both in vivo and in vitro.

Authors:  Weiliang Yan; Xiaodong Huo; Huixing Wang; Bin Huo; Yongtao Guo; Hua Dong; Guangjun Zheng; Junjie Wang; Shude Chai; Haitao Wang; Zuncheng Zhang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

Review 9.  Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers.

Authors:  Jesse B Wolinsky; Yolonda L Colson; Mark W Grinstaff
Journal:  J Control Release       Date:  2011-12-01       Impact factor: 9.776

Review 10.  Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients.

Authors:  Guy C Jones; Jason D Kehrer; Jenna Kahn; Bobby N Koneru; Ram Narayan; Tarita O Thomas; Kevin Camphausen; Minesh P Mehta; Aradhana Kaushal
Journal:  Clin Lung Cancer       Date:  2015-04-23       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.